Search Results

Excision BioTherapeutics, Inc. today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.

Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure latent viral infectious diseases, summarized the novel presentation of multiple studies at this week’s American Society of Gene and Cell Therapy (ASGCT) meeting.

Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.

Excision BioTherapeutics, Inc. (“Excision”, the “Company”) today announced that it will present positive data from its herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Excision BioTherapeutics, Inc. today announced that it will deliver an oral presentation highlighting new data from its herpes simplex virus-1 keratitis (HSV-1 Keratitis) program, EBT-104, at CRISPRMED24, the CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, Excision BioTherapeutics’ HIV gene editor failed to suppress viral activity.

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, announced that it will present positive data from its program for Hepatitis B virus at the American Society of Gene & Cell Therapy 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.